or IIA cervical carcinoma underwent a
Surgical management of stage IB-IIA cervical carcinoma
โ Scribed by Daniel M. Donato
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 32 KB
- Volume
- 16
- Category
- Article
- ISSN
- 8756-0437
No coin nor oath required. For personal study only.
โฆ Synopsis
The standard surgical approach to Stage IB and IIA cervical cancer consists of a radical hysterectomy, lower peri-aortic lymphadenectomy, and complete bilateral pelvic lymphadenectomy. This approach offers 5-year survival rates of 75% to 90% in most large series, which is equivalent to the radiotherapeutic treatment of this disease. Over the last 50 years, this classic surgical approach has undergone only minor modifications. The present day complication rate remains low, and is comparable to that of radiotherapy. This article will summarize the current indications, pre-, intra-, and post-operative management of this disease.
๐ SIMILAR VOLUMES
Radical hysterectomy and bilateral pelvic lymphadenectomy were done on 875 patients diagnosed with cervical carcinoma Stages IB (484 patients), IIA (96 patients), and IIB (295 patients), The number of positive nodes was 0 in 620 patients (NO), one in 98 patients (Nl), two to three in 80 patients (NZ
For patients with lung cancer, the greatest hope for cure rests with patients with early stage disease. Surgery has been the standard of care for this group with the best 5-year survival of only 65% being achieved in patients with earliest pathologic Stage IA disease. Using strategies gained from th
Since the early 1940s, the incidence of cervical cancer has dramatically decreased due in large part to the work of Papanicolaou and Traut. Successful treatment can now be done using simple or radical surgical intervention for early invasive lesions and radiation therapy for more advanced lesions. H
welve to twenty-eight percent of patients newly diagnosed with T prostate carcinoma have disease clinically classified as T3.I.' Radical prostatectomy for these patients with clinical T3 prostate carcinoma can be safely performed with acceptable morbidity, but this has not been a widely accepted or